Brief: Ribomic Announces Positive Phase 2 Cohort 2 Results For Umedaptanib Pegol In Achondroplasia
07/10/2025 07:41
Oct 7 (Reuters) - Ribomic Inc 4591.T: RIBOMIC ANNOUNCES POSITIVE PHASE 2 COHORT 2 RESULTS FOR UMEDAPTANIB PEGOL IN ACHONDROPLASIA, DEMONSTRATING AN INCREASE IN THE ANNUALIZED GROWTH RATE OF UP TO +5.0 CM/YEAR WITH BIWEEKLY ADMINISTRATION IN CHILDREN AGED 5 YEARS AND OLDER PHASE 3 TRIAL SCHEDULED TO BEGIN IN Q1 FISCAL YEAR 2026 ((Reuters.Briefs@thomsonreuters.com;;))